Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $17.84 and traded as high as $22.30. Teva Pharmaceutical Industries shares last traded at $21.30, with a volume of 8,123,668 shares traded.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of analyst reports. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.88.

Teva Pharmaceutical Industries Trading Down 0.3 %

The company’s 50 day simple moving average is $18.60 and its two-hundred day simple moving average is $17.87. The company has a market capitalization of $24.06 billion, a price-to-earnings ratio of -24.99, a P/E/G ratio of 0.99 and a beta of 0.73. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently modified their holdings of the stock. Coronation Fund Managers Ltd. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $1,334,000. Ritholtz Wealth Management purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $183,000. Natixis Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 27.5% during the 2nd quarter. Natixis Advisors LLC now owns 201,352 shares of the company’s stock valued at $3,272,000 after acquiring an additional 43,373 shares during the period. CIBC Asset Management Inc increased its stake in shares of Teva Pharmaceutical Industries by 3.4% in the 2nd quarter. CIBC Asset Management Inc now owns 99,750 shares of the company’s stock valued at $1,621,000 after purchasing an additional 3,325 shares in the last quarter. Finally, TD Asset Management Inc raised its holdings in Teva Pharmaceutical Industries by 1.2% in the 2nd quarter. TD Asset Management Inc now owns 225,109 shares of the company’s stock worth $3,658,000 after purchasing an additional 2,621 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.